NCT07140562招募中不适用
Prospective, Multi-Center, Single-Arm Study: Safety and Technical Feasibility of the Tangent Tricuspid Annular Therapy System for Transcatheter Valve Repair in Patients With Severe, Symptomatic Functional Tricuspid Regurgitation
Tangent Cardiovascular Inc.1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2025年7月15日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Primary Safety Endpoint: Proportion of Patients Free From Device or Procedure-Related Major Adverse Events (MAEs) Through 30-Days Post-Procedure
研究概览
简要总结
The goal of this clinical trial is to evaluate the safety and technical success of the Tangent Tricuspid Annular Therapy System in patients with severe, symptomatic functional tricuspid regurgitation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-90 years old at the time of consent
- •Symptomatic functional tricuspid regurgitation (without co-existing degenerative disease) despite being adequately treated with optimal medical therapy by the Local Heart Team for at least 30 days prior to the study consent
- •Severe, massive or torrential functional tricuspid regurgitation, as determined by qualifying transesophageal echocardiogram (TEE) and/or transthoracic echocardiogram (TTE) using the 5-grade classification
- •TEE imaging confirms adequate visualization of valve for TR quantification and procedural guidance
- •The Local Heart Team determines the candidate is suitable for transcatheter tricuspid valve repair
- •Subject or legally authorized representative has provided informed consent and agrees to return for all required post-procedure follow-up visits
排除标准
- •Estimated life expectancy of less than 12 months
- •Systolic pulmonary artery pressure (sPAP) >70 mmHg as assessed by TTE or right heart catheterization
- •Acutely decompensated, defined as hypotension with SBP <90 mmHg, use of hemodynamic support devices or inotropes or uncontrolled arterial hypertension with SBP >180 mmHg within 30 days of the study procedure
- •Severe COPD dependent on home oxygen or chronic home oxygen use
- •Echocardiographic evidence of severe right ventricular dysfunction
- •Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation requiring treatment (prior transcatheter or surgical treatment allowable)
- •Any condition that would interfere with the procedure, such as prior tricuspid valve repair, tricuspid valve leaflet anatomy which may preclude device implantation, pacemaker or Implantable Cardioverter Defibrillator (ICD) leads that would prevent appropriate placement or visualization of implant, Ebstein Anomaly (normal annulus position, but valve leaflets attached to walls and septum of the right ventricle)
- •Tricuspid valve stenosis defined as a tricuspid valve orifice of ≤1.0 cm2 and/or mean gradient of ≥5 mmHg
- •New or untreated right heart chamber and/or superior vena cava intracardiac mass, thrombus, or vegetation
- •Degenerative tricuspid or rheumatic tricuspid valve disease
- •Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days of the study procedure
- •Implant or revision of any rhythm management device (CRT or CRT-D, ICD, or leadless pacemaker) within 90 days prior to the study procedure
- •Known need for emergent, urgent, or planned surgery or intervention within 30 days following the study procedure, or planned or scheduled cardiac surgery within 12 months following the study procedure
- •Stroke or other major cerebrovascular event within 90 days prior to the study procedure
- •Untreated clinically significant coronary artery disease requiring revascularization, recent (within 30 days of the study procedure) acute coronary syndrome or myocardial infarction
- •Active or recent GI bleed within 30 days prior to the study procedure, or patients contraindicated for oral anticoagulation therapy
- •Bleeding disorders including thrombocytopenia (platelet count <70,000 mm3) or thrombocytosis (platelet count >700,000 mm3)
- •Transfusion-dependent chronic anemia with Hb <9/dL
- •Current or planned pregnancy within 12 months of the study procedure for women of childbearing potential
- •Active or recent endocarditis within 90 days of the study procedure, or sepsis/other systemic infection requiring oral or intravenous antibiotics within 30 days of the study procedure
- •Prior tricuspid repair or tricuspid replacement or prosthetic implant that would interfere with successful deployment or functioning of the Tangent Implant
- •Participation in another pre-market investigational device study or investigational drug study (for a cardiac-related drug)
- •Presence of other anatomic or co-morbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's availability to participate in the clinical investigation or to comply with follow-up requirements
- •Any patient considered to be vulnerable
- •Left ventricular ejection fraction (LVEF) <30%
- •Deep vein thrombosis or pulmonary embolism within 6 months of the study procedure
- •Child-Pugh C cirrhosis
研究组 & 干预措施
Tangent Tricuspid Annular Therapy System Treatment Group
Experimental
Subjects will receive the experimental device according to the protocol. Primary safety and technical efficacy will be assessed, as well as secondary performance measures.
干预措施: Tricuspid Annular Therapy System (Device)
结局指标
主要结局
Primary Safety Endpoint: Proportion of Patients Free From Device or Procedure-Related Major Adverse Events (MAEs) Through 30-Days Post-Procedure
时间窗: 30 days post-procedure
Freedom from device or procedure-related major adverse events (MAEs) through 30 days post-procedure, including: * Cardiovascular mortality * Stroke * Myocardial infarction * Major cardiac structural complications * Device-related pulmonary embolism (PE) * Severe bleeding defined by MVARC * Unplanned tricuspid valve re-intervention (percutaneous or surgical)
Primary Technical and Efficacy Endpoint - Measure 1: Technical Success at Completion of the Procedure
时间窗: At completion of the index procedure
Technical success upon completion of the procedure in the catheterization lab or operating room, defined as: 1. Successful delivery and removal of the Delivery System; 2. Device implanted in the patient as intended.
Primary Technical and Efficacy Endpoint - Measure 2: Procedural Technical Success and TR ≤Moderate at Hospital Discharge
时间窗: At hospital discharge following the index procedure
Procedural success at discharge, defined as: 1. Achieved technical success; 2. TR classification of moderate or less
次要结局
- Secondary Endpoint - 6MWT at 30, 90, 180, and 365-Days Post-Procedure(30 days (±7 days); 90 days (±30 days); 180 days (±30 days); 365 days (±60 days))
- Secondary Endpoint - NYHA Functional Class at 30, 90, 180, and 365-Days Post-Procedure(30 days (±7 days); 90 days (±30 days); 180 days (±30 days); 365 days (±60 days))
- Secondary Endpoint - KCCQ at 30, 90, 180, and 365-Days Post-Procedure(30 days (±7 days); 90 days (±30 days); 180 days (±30 days); 365 days (±60 days))
- Secondary Endpoint - Tricuspid Regurgitation at 30, 90, 180, and 365-Days Post-Procedure(30 days (±7 days); 90 days (±30 days); 180 days (±30 days); 365 days (±60 days))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary LesionsCoronary Artery DiseaseNCT01092416Abbott Medical Devices443
招募中
不适用
IBS Titan™ Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System Clinical TrialInfrapopliteal LesionsCritical Limb IschemiaNCT05971394Biotyx Medical (Shenzhen) Co., Ltd.100
已完成
不适用
Staged Bilateral Exablate Treatment of Medication Refractory Essential TremorEssential TremorNCT03465761InSightec7
尚未招募
不适用
Safety and Efficacy Evaluation of ArtiFix® Sealant Graft in Subjects Requiring Dural Repair Following NeurosurgeryDural TearCerebrospinal Fluid LeakNCT07092267Nurami Medical Ltd20
已完成
不适用
Sunstone IPL (Intense Pulsed Light) for Hair ReductionHair RemovalNCT03921814Philips Healthcare102